# US 2025/0154288 A1 · Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154288 A1
- Document ID: US20250154288A1
- Status: Published application
- Kind: A1
- Application number: 18/800,888
- Filed: 2024-08-12
- Published: 2025-05-15
- Earliest claimed: 2022-02-25
- Assignees: GlaxoSmithKline Intellectual Property Development Limited
- Applicants: Glaxosmithkline Intellectual Property Development Limited
- Inventors: Jae U. Jeong; Valer Jeso; Beth Anne Knapp-Reed; Andrew Peter Marcus; James P. Phelan; Matthew Robert Sender; Brandon James Turunen
- Web page: https://patentgrep.com/patent/US20250154288A1

## CPC

- A61K 47/555: {pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 39/39583: {against materials not provided for elsewhere, e.g. haptens, coenzymes}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 471/04: Ortho-condensed systems
- C07K 16/16: against material from plants
- A61K 2039/505: {comprising antibodies}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof,
wherein:
T is
R1 is C1-4 alkyl or C3-6 cycloalkyl;
L is a divalent linker of Formula (L-a), (L-b), (L-c), (L-d), or (L-e):
or a stereoisomer thereof,
wherein:
Ring A and Ring B are each independently C4-6 cycloalkylene;
L1a is C3-5 linear alkylene, wherein 1 or 2 methylene units are replaced with —O— or —NRa—;
each Ra is independently hydrogen or C1-3 alkyl; and
L2a is —O—, —NHC(O)—, or —CH2—O—;
or a stereoisomer thereof,
wherein:
Ring A is C4-6 cycloalkylene or C7-9 bridged bicyclic cycloalkylene;
L1b is —CH2—NH—C(O)—, —NHC(O)—, or —C(O)NH—;
L2b is C6-12 linear alkylene, wherein 1, 2, 3, or 4 methylene units are replaced with —O—, —NR1b—, —C(O)NR1b—, or —NR1bC(O)—; or
L2b is
wherein n is 1, 2, 3, or 4, and
represents a covalent bond to L1b; and
each R1b is independently hydrogen or C1-3 alkyl;
or a stereoisomer thereof,
wherein:
L1c is C2-10 linear alkylene, wherein 1, 2, or 3 methylene units are replaced with —O—, —NH—, —NHC(O)—, or —C(O)NH—;
Ring A is C4-6 cycloalkylene or C7-9 bridged bicyclic cycloalkylene; and
L2c is —O— or a saturated C2-10 linear alkylene, wherein 1, 2, or 3 methylene units are replaced with —O—, —NH—, —NHC(O)—, or —C(O)NH—;
wherein:
L1d is C12-30 linear alkylene, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 methylene units are replaced with —NH—, —O—, —C(O)NH—, —NHC(O)—, or —NHC(O)—NH—; or
wherein n is an integer of 3 to 50;
wherein each
represents a covalent bond to the Y group of Formula (I), or when Y is a bond, a covalent bond to the T group of Formula (I), and each
represents a covalent bond to the methylene group of Formula (I); and
Y is a bond or a divalent spacer moiety of one to twelve atoms in length.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is —CH3.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-a-i):
or a stereoisomer thereof,
wherein Ring A L1a, L2a,
and are as defined for Formula (L-a).

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-a-ii):
or a stereoisomer thereof,
wherein L1a, L2a,
and are as defined for Formula (L-a); p is 1 or 2; and m is 1 or 2.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-a-iii):
or a stereoisomer thereof,
wherein p is 1 or 2; m is 1 or 2; n is 1, 2, or 3; and
are as defined for Formula (L-a).

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-a) selected from the group consisting of:

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-b-i):
or a stereoisomer thereof,
wherein L1b, L2b,
and are as defined for Formula (L-b); p is 1 or 2; and m is 1 or 2.

### Claim 8 (depends on 1)

The compound of claim 1, wherein L is a divalent linker of Formula (L-b) selected from the group consisting of:

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-c-i):
or a stereoisomer thereof,
wherein L1c, L2c,
and are as defined for Formula (L-c); p is 1 or 2; and m is 1 or 2.

### Claim 10 (depends on 1)

The compound of claim 1, wherein L is a divalent linker of Formula (L-c) selected from the group consisting of

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein L is a divalent linker of Formula (L-d) selected from the group consisting of:

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Y is selected from a bond; —NH—; —(C1-12 alkylene)-, wherein 1, 2, or 3 methylene units are replaced with —O—, —NH—, —C(O)—, —NHC(O)—, —C(O)NH—, —(C3-6 cycloalkylene)-, —(C3-6 cycloalkenylene)-, 3- to 6-membered heterocycloalkylene, arylene, or heteroarylene; or —(C2-12 alkenylene)-, wherein 1, 2, or 3 methylene units are replaced with —O—, —NH—, —C(O)—, —NHC(O)—, —C(O)NH—, —(C30.6 cycloalkylene)-, —(C3-6 cycloalkenylene)-, 3- to 6-membered heterocycloalkylene, arylene, or heteroarylene.

### Claim 13 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein Y is selected from a bond; —NH—; —(C1-6 alkylene)-O—; —(C2-6 alkenylene)-O—; —(C1-6 alkylene)-C(O)—; —(C2-6 alkenylene)-C(O)—; phenylene; piperidinylene; —(C1-6 alkylene)-O-phenylene-; —(C2-6 alkenylene)-O-piperidinylene; —(C1-5 alkylene)-NH—, wherein 0, 1, or 2 methylene units are replaced with —O—; —NH—(C1-5 alkylene)-NH—; —(C3-6 cycloalkylene)-NH—; —(C3-6 cycloalkenylene)-NH—; or
wherein Y1a is a bond, —O—, —NH—, —NHC(O)—, —C(O)NH—, or C1-3 alkylene; and Y2a is a bond, —O—, —NH—, —NHC(O)—, —C(O)NH—, or C1-3 alkylene.

### Claim 14 (depends on 6)

The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of:

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is a compound in Table 1 or a pharmaceutically acceptable salt thereof.

### Claim 16

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A method of treating and/or preventing a disease or disorder in a patient in need thereof, the method comprising: administering to the patient a therapeutically effective amount of the compound of claim 1 and an anti-cotinine antibody, or antigen-binding fragment thereof, wherein the disease or disorder is selected from a cancer, an inflammatory disease, an autoimmune disease, a viral infection, or a bacterial infection.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease or disorder is mediated by chemokine receptor 2 (CCR2) and/or is associated with CCR2-positive pathogenic cells.

### Claim 19 (depends on 17)

The method of claim 17, wherein the disease is a cancer that is a solid tumor.

### Claim 20 (depends on 17)

The method of claim 17, wherein the disease or disorder is a cancer selected from leukemia, lymphoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), colorectal cancer (CRC), cervical squamous cell carcinoma (CESC), head and neck squamous cell carcinoma (HNSC), pancreatic cancer, metastatic castration-resistant prostate cancer (mCRPC), ovarian cancer, bladder cancer, or breast cancer.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A method of increasing antibody-dependent cell cytotoxicity (ADCC) of C—C motif chemokine receptor 2 (CCR2)-expressing cells, the method comprising: contacting the cells with an effective amount of the compound of claim 1 and an anti-cotinine antibody, or antigen-binding fragment thereof, wherein the CCR2-binding moiety of the compound binds the CCR2 expressed on the cells.

### Claim 24 (depends on 1)

A method of depleting C—C motif chemokine receptor 2 (CCR2)-expressing cells, the method comprising: contacting the cells with an effective amount of the compound of claim 1 and an anti-cotinine antibody, or antigen-binding fragment thereof, wherein the CCR2-binding moiety of the compound binds the CCR2 expressed on the cells.

### Claim 25

(canceled)

### Claim 26 (depends on 20)

The method of claim 20, wherein the anti-cotinine antibody has a heavy chain and a light chain, the heavy chain comprising a CDR1 having SEQ ID NO: 1, a CDR2 having SEQ ID NO: 2, and a CDR3 having SEQ ID NO: 3, and the light chain comprising a CDR1 having SEQ ID NO: 4, a CDR2 having SEQ ID NO: 5, and a CDR3 having SEQ ID NO: 6.

### Claim 27 (depends on 20)

The method of claim 20, wherein the anti-cotinine antibody has a heavy chain and a light chain, the heavy chain comprising a heavy chain variable region (VH) having SEQ ID NO: 7, and the light chain comprising a light chain variable region (VL) having SEQ ID NO: 8.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 20)

The method of claim 20, wherein the anti-cotinine antibody has a heavy chain comprising SEQ ID NO: 9 and a light chain comprising SEQ ID NO: 10.

### Claim 31 (depends on 1)

A combination comprising the compound of claim 1, and an anti-cotinine antibody, or antigen-binding fragment thereof.

### Claim 32 (depends on 31)

The combination of claim 31, wherein the anti-cotinine antibody has a heavy chain and a light chain, the heavy chain comprising a CDR1 having SEQ ID NO: 1, a CDR2 having SEQ ID NO: 2, and a CDR3 having SEQ ID NO: 3, and the light chain comprising a CDR1 having SEQ ID NO: 4, a CDR2 having SEQ ID NO: 5, and a CDR3 having SEQ ID NO: 6.

### Claim at position 33

33-36. (canceled)
